Reduced Expression of CD62L Is Associated with Increased ADAM1 7 Activity and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP)

Sieghart Sopper,Satu Mustjoki,Angelica Loskog,Bjørn Tore Gjertsen,Ute Mark,Jens Haenig,Nidas Jurjonas,Günther Gastl,F. Giles,Andreas Hochhaus,Gert J. Ossenkoppele,Kimmo Porkka,Dominik Wolf

Reduced Expression of CD62L Is Associated with Increased ADAM1 7 Activity and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP)

2014

Sieghart Sopper
Satu Mustjoki
Angelica Loskog
Bjørn Tore Gjertsen
Ute Mark
Jens Haenig
Nidas Jurjonas
Günther Gastl
F. Giles
Andreas Hochhaus
Gert J. Ossenkoppele
Kimmo Porkka
Dominik Wolf

Reduced Expression of CD62L Is Associated with Increased ADAM1 7 Activity and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP)

Keywords:

Nilotinib
Hematology
Immunology
Molecular Response
Chronic phase chronic myelogenous leukemia
Medicine
Internal medicine
Cancer research
Surrogate endpoint
Whole blood
Oncology
L-selectin
Stem cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations